Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET
Company Participants
Lee Roth – President, Burns McClellan, Investor Relations Advisors
Vipin Garg – Chief Executive Officer
Scott Harris – Chief Medical Officer
Greg Weaver – Chief Financial Officer
Scot Roberts – Chief Scientific Officer
Conference Call Participants
Yasmeen Rahimi – Piper Sandler
Liisa Bayko – Evercore
Roger Song – Jefferies
Annabel Samimy – Stifel
Mayank Mamtani – B Riley
Andy Hsieh – William Blair
Operator
Good day, ladies and gentlemen, and welcome to Altimmune First Quarter 2025 Financial Results Conference Call. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded.
I’ll now introduce your host for today’s conference call, Lee Roth, President of Burns McClellan, Investor Relations Advisors to Altimmune. Lee, you may begin.
Lee Roth
Thanks Gigi. Good morning everyone. Once again thank you all for joining us for Altimmune’s first quarter 2025 financial results and business update conference call.
On today’s call you will hear from Dr. Vipin Garg, our Chief Executive Officer; Dr. Scott Harris, our Chief Medical Officer; and Greg Weaver, our Chief Financial Officer. Dr. Scot Roberts, our Chief Scientific Officer and Ray Jordt, our Chief Business Officer will join us for the Q&A session.
Our first quarter 2025 results and corporate update press release was issued earlier this morning and can be found on the Investor Relations section of the Altimmune website. Before we begin, I’d like to remind everyone that remarks made about future expectations, plans and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.
Read the full article here